. Author manuscript; available in PMC: 2018 May 1.

Published in final edited form as: Hepatology. 2017 Mar 31;65(5):1557–1565. doi: 10.1002/hep.29085

Table 1.

Included Studies Reporting Mortality Associated with NAFLD Fibrosis

Author, Publication Year	Location, Time Period	NAFLD sub-type, n	Men, n (%)	Age, mean/median years	Body Mass Index (BMI, kg/m2)	Comorbidities	Mean/Median Follow-up Time (years)	Study Quality^*
Younossi⁹, 2011 Retrospective	USA	NAFL 78 NASH 132	79 (38%)	NAFLD - 48.1 NASH - 49.1	NAFL BMI: 34.9 ± 10.8 NASH BMI: 37.4 ± 10.3	Obese: 102 DM: 43 HLD: 47	Median 12.17 Max 28.5	HIGH
Sebastiani¹⁶, 2015 Retrospective	Canada, 2004–2013	NASH 148	103 (70%)	49.5	31.3 ± 5.4	Obese: 74 DM: 49 HTN: 58 Met Synd: 42	Median 5	HIGH
Ekstedt¹⁰, 2015 Prospective	Sweden, 1980–1993	NAFLD 229	149 (65%)	48.8	28.3 ± 3.7	Obese: 59 DM: 31 HTN: 130 HLD: 78	Mean 26.4 ± 5.6 Range 6 – 33	HIGH
Angulo¹¹, 2015 Retrospective	Multi-national, 1975–2005	NAFL 335 NASH 284	232 (38%)	49	30.7	DM: 232 HTN: 190	Median 12.6 Range 0.3 – 35.1	HIGH
Leung¹⁷, 2016 Prospective	Hong Kong, 2006–2015	NAFL 156 NASH 151	171 (56%)	51	27.6	DM: 170 HTN: 170 Met Synd: 186	Median 4.1 (IQR 11 – 82 months)	HIGH

Based on the modified Newcastle-Ottawa scale for cohort studies. See Supplementary Table 1

NAFL: Non-alcoholic fatty liver; NASH: Non-alcoholic steatohepatitis; DM: Diabetes mellitus; HTN: hypertension; Met Synd: Metabolic syndrome; BMI: Body mass index; IQR: interquartile range